Xiao Hui Gu
Plus aucun poste en cours
Profil
Xiao Hui Gu worked as an Executive Director of Medicinal Chemistry at Pharmaron Beijing Co., Ltd.
and as a Principal at Exelixis, Inc. Prior to that, from 2001 to 2008, Gu worked at X-Ceptor Therapeutics, Inc. as a Principal.
Gu received an undergraduate degree from Hunan Normal University and graduate and doctorate degrees from Shanghai Institute of Organic Chemistry.
Anciens postes connus de Xiao Hui Gu
| Sociétés | Poste | Fin |
|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | 01/01/2008 |
| EXELIXIS, INC. | Corporate Officer/Principal | - |
| PHARMARON BEIJING CO., LTD. | Corporate Officer/Principal | - |
Formation de Xiao Hui Gu
| Hunan Normal University | Undergraduate Degree |
| Shanghai Institute of Organic Chemistry | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PHARMARON BEIJING CO., LTD. | Commercial Services |
| EXELIXIS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
